Double-blind, Placebo-controlled Study on Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia to Assess Changes in Pressure Flow Study and in Molecular Profile of Prostatic Tissue After 12 Weeks Treatment With Tadalafil

Trial Profile

Double-blind, Placebo-controlled Study on Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia to Assess Changes in Pressure Flow Study and in Molecular Profile of Prostatic Tissue After 12 Weeks Treatment With Tadalafil

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2015

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Dec 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 26 May 2015 Planned End Date changed from 1 Nov 2017 to 1 Apr 2019, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top